Alnylam Pharmaceuticals (ALNY) Assets Average (2010 - 2026)
Alnylam Pharmaceuticals posted quarterly Assets Average of $5.0 billion for Q1 2026, up 19.42% year-on-year from $4.2 billion in Q1 2025, and up 2.83% on a QoQ basis from $4.9 billion in Q4 2025.
Alnylam Pharmaceuticals (ALNY) has 17 years of Assets Average data on file, last reported at $5.0 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets Average rose 19.42% year-over-year to $5.0 billion; the trailing twelve-month figure through Mar 2026 stood at $5.0 billion (up 19.42% YoY), and the FY2025 full-year result was $4.6 billion, up 14.08% from the prior year.
- Assets Average for Q1 2026 stood at $5.0 billion, up from $4.9 billion in the prior quarter.
- Across five years, Assets Average topped out at $5.0 billion in Q1 2026 and bottomed at $3.4 billion in Q2 2022.
- The 5-year median for Assets Average is $3.8 billion (2023), against an average of $4.0 billion.
- The widest annual swing landed in 2023, when Assets Average dropped 1.96%; it then advanced 19.42% in 2026.
- A 5-year view of Assets Average shows it stood at $3.5 billion in 2022, then grew by 8.29% to $3.8 billion in 2023, then rose by 10.12% to $4.2 billion in 2024, then increased by 16.26% to $4.9 billion in 2025, then rose by 2.83% to $5.0 billion in 2026.
- The last three Assets Average figures came in at $5.0 billion (Q1 2026), $4.9 billion (Q4 2025), and $4.7 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | 2.30 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.05 Bn |
| Dec 31, 2025 | 4.91 Bn |
| Sep 30, 2025 | 4.71 Bn |
| Jun 30, 2025 | 4.39 Bn |
| Mar 31, 2025 | 4.23 Bn |
| Dec 31, 2024 | 4.22 Bn |
| Sep 30, 2024 | 4.11 Bn |
| Jun 30, 2024 | 3.92 Bn |
| Mar 31, 2024 | 3.83 Bn |
| Dec 31, 2023 | 3.83 Bn |
| Sep 30, 2023 | 3.62 Bn |
| Jun 30, 2023 | 3.40 Bn |
| Mar 31, 2023 | 3.47 Bn |
| Dec 31, 2022 | 3.54 Bn |
| Sep 30, 2022 | 3.43 Bn |
| Jun 30, 2022 | 3.38 Bn |
| Mar 31, 2022 | 3.54 Bn |
| Dec 31, 2021 | 3.56 Bn |
| Sep 30, 2021 | 3.49 Bn |
| Jun 30, 2021 | 3.38 Bn |
| Mar 31, 2021 | 3.33 Bn |
| Dec 31, 2020 | 3.36 Bn |
| Sep 30, 2020 | 3.34 Bn |
| Jun 30, 2020 | 2.83 Bn |
| Mar 31, 2020 | 2.34 Bn |
| Dec 31, 2019 | 2.47 Bn |
| Sep 30, 2019 | 2.63 Bn |
| Jun 30, 2019 | 2.37 Bn |
| Mar 31, 2019 | 1.79 Bn |
| Dec 31, 2018 | 1.63 Bn |
| Sep 30, 2018 | 1.73 Bn |
| Jun 30, 2018 | 1.86 Bn |
| Mar 31, 2018 | 1.96 Bn |
| Dec 31, 2017 | 1.68 Bn |
| Sep 30, 2017 | 1.40 Bn |
| Jun 30, 2017 | 1.28 Bn |
| Mar 31, 2017 | 1.20 Bn |
| Dec 31, 2016 | 1.29 Bn |
| Sep 30, 2016 | 1.35 Bn |
| Jun 30, 2016 | 1.35 Bn |
| Mar 31, 2016 | 1.35 Bn |
| Dec 31, 2015 | 1.41 Bn |
| Sep 30, 2015 | 1.48 Bn |
| Jun 30, 2015 | 1.58 Bn |
| Mar 31, 2015 | 1.35 Bn |
| Dec 31, 2014 | 1.03 Bn |
| Sep 30, 2014 | 1.01 Bn |
| Jun 30, 2014 | 1.06 Bn |
| Mar 31, 2014 | 750.41 Mn |
| Dec 31, 2013 | 434.02 Mn |
| Sep 30, 2013 | 455.03 Mn |
| Jun 30, 2013 | 467.07 Mn |
| Mar 31, 2013 | 379.55 Mn |
| Dec 31, 2012 | 304.94 Mn |
| Sep 30, 2012 | 320.41 Mn |
| Jun 30, 2012 | 329.39 Mn |
| Mar 31, 2012 | 311.11 Mn |
| Dec 31, 2011 | 296.07 Mn |
| Sep 30, 2011 | 325.53 Mn |
| Jun 30, 2011 | 354.94 Mn |
| Mar 31, 2011 | 381.16 Mn |
| Dec 31, 2010 | 402.94 Mn |
| Sep 30, 2010 | 426.39 Mn |